.jpg?w=340&itok=TLcMGdom "EPR in healthcare news."){kind=icon}
Happy Holidays from all of us at ICON. We’re sending every best wish for health, happiness and success in 2026.
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
The power of partnership: Collaborating with patient advocacy organisations for better clinical research
Laura Iliescu explores the powerful potential of collaboration with PAOs for clinical trials, particularly how PAOs can inform trial design and the creation of patient registries.
-
Inclusive approaches to diversity and inclusion
Devra Densmore, Senior Lead of Patient Advocacy Strategy at the Centre for Rare Diseases at ICON, discusses the importance of DEI in rare disease clinical trials and shares actionable points for a more inclusive approach.
-
Rare disease drug development
In this article, Will Maier outlines the importance of utilising real world evidence from rare diseases in accelerating product approval and development.
-
.jpg?w=545&itok=Sxc2gJVj "EPR in healthcare news.")
Using RWE in rare disease drug development: effective innovations with historical controls
With a growing number of therapies under development for rare diseases, William Maier discusses how real-world evidence can be effectively used as a historical control, overcoming challenges presented in clinical development.
-
How real world evidence is impacting rare disease drug development
Will Maier, VP of Rare Diseases, shares how a more patient-focused approach to trials is leading to alternatives for randomisation.
-
Real world evidence and the patient experience: Involving rare disease patients for successful trials
ICON's William C Maier and Maggie Adamski discuss case studies from their line of work, and how real world evidence can support those suffering with rare diseases around the world.
-
An overview on rare disease research
ICON's Tim Clark and Will Maier examine the key clinical, regulatory, and commercial challenges associated with the development of therapies for the treatment of rare diseases.
-
Using Historical Controls for Rare Disease Trials: Challenges and Opportunities
The use of historical controls in rare disease trials, using existing medical history information on a group of similar patients, rather than using a traditional placebo group, is gaining industry and regulatory support. Will Maier discusses challenges and opportunities in the Autumn 2019 issue of Pharmafile.
-
Intricacies of Precision Medicine for Biotechs
Andrew Garrett discusses challenges such as patient recruitment for biotechs developing therapies for targeted populations with rare diseases.
-
Rare disease trials Q&A
A Pharmaceutical Market Europe (PME) Q&A article authored by Gretchen Goller and Valerie Legrand, discussing the challenges of rare disease trials, including those of recruitment and retention unique to rare disease studies. The article also provides insights on solutions to these challenges.
